Omer Ashruf
@omerashruf
MS4 @NEOMEDedu | Interested in Public Health Informatics • Plasma Cell Disorders • Stem Cell Transplantation | Views are my own
ID: 1640842713917431810
28-03-2023 22:26:16
23 Tweet
60 Followers
49 Following
Excited to share that our manuscript got accepted by Antibodies by MDPI. Thank you Faiz Anwer MD for supervising it. Thanks to my co-authors for their contribution Zunairah Shah Pranali Pachika Saba Link: mdpi.com/2073-4468/12/2…
Great interview with Renal & Urology News regarding our study of Nirmatrelvir/Ritonavir (Paxlovid) in moderate and severe CKD patients presented at American Society of Nephrology! Antiviral Nirmatrelvir-Ritonavir Cuts Hospitalization, Death Risks in CKD With COVID-19 renalandurologynews.com/conference-hig…
It was great meeting you at Ohio State Medical, Dr. Wee!! Would not have been possible without the mentorship of Faiz Anwer MD and Dr Rupesh Raina MD
A much needed seminar applicable to mentors/mentees at all stages of training/practice. Thank you Anusha Agarwal, MD Richard M. Wardrop III, MD, PhD, MACP, SFHM, FAAP ACP Ohio , looking forward to the next!
Have a #story to tell? Please join us for our 2nd Annual #StorySlam at the ACP Ohio / Air Force Annual Meeting! This year’s theme: “#Kindness Rules”! Eileen Barrett MD MPH (she/her) has already agreed to share a story! Who is next? Jacqueline Baikovitz, MD, MPH Med Peds Hospitalist Arunab Mehta, MD, MEd, FHM Omer Ashruf
Excited and humbled to share our multicenter study published in JGIM Journal of General Internal Medicine on Paxlovid in Stage 3–5 (eGFR < 60) CKD patients with COVID-19! Many thanks to our incredible team! link.springer.com/article/10.100… NEOMED Dr Rupesh Raina MD Razwana Khanam ACP Ohio Richard M. Wardrop III, MD, PhD, FAAP, FACP, SFHM SGIM
👀 7,026 patients with : 💠 Moderate-severe #CKD 💠 #COVID19 Nirmatrelvir/Ritonavir was assoctd w/ risk reductions in all-cause hospitalization, ICU admission, mechanical ventilation, and mortality at 90 and 365 days. Omer Ashruf Dr Rupesh Raina MD @NEOMEDEdu buff.ly/4h57YDP